REGENXBIO Investor update
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay. I have got the thumbs up from the back, so we are ready to go. This is a really special day. I have been thrilled to be working in something new, which 11 years ago started out on a program at UPenn, starting with RGX-314, and here we are in the vicinity of top-line data. I am really thrilled that today is more or less an exposé of the program, rethinking where we are, thinking about the commercial opportunity, looking at the clinical data, and the unmet need. We are just thrilled to have you all join us today. Just a note that I will be making forward-looking statements today, as well as some of the panelists. I will not read this entire slide to you, so there is that.
Those of you that are maybe a little less familiar with Regenxbio, this is a really transformational, not year, but even quarter in terms of upcoming events. We have been at this for roughly 15 years. Started out in the first 5 years out-licensing our technology primarily. Then in the last 10 years, beginning internal development of the program, some of which you will see today. We have over 20 licensees developing in the field. I use the example of Zolgensma as one of the success stories from the NAV technology in terms of showing what gene therapy can deliver. In particular, today, we will talk a little bit about the sura-vec program, which has partnered with AbbVie in a broad spectrum of retinal disease areas.
In particular today, we will talk about the wet AMD program, which is delivered subretinally, where we expect to show top-line results in Q4 of this year. We have been able to show over the last few months, long-term data supporting that top-line data release that will come soon. Not too far behind it, we have excitement around the rare disease programs with our Duchenne program in which we are anticipating a pre-BLA meeting by the end of this year and then filing a BLA for that program in Q1 of next year. We are really turning the corner in terms of setting up 2027 to be a year where we move substantially towards commercialization. Because I came out of operations, I always get to throw a manufacturing slide in, and this one will be no different.
One of the unique features of us as a gene therapy company is our in-house manufacturing, and some of our panelists have been gracious enough to come visit and see this in action. We have the capability in the Rockville plant to produce close to 350,000 doses per year of sura-vec. So a substantial capacity on ocular, and then in the rare disease for Duchenne, which is a very high vector requirement, up to 2,500 doses per year. The facility was inspected last year as part of our RGX-121 program, and it is really rare for a new facility to go through an inspection with no observations. We are pointing that forward to sura-vec and to the Duchenne program as something that we feel really strong. Being positioned for commercial readiness on the manufacturing side is really critical.
Being able to make vector, which is highly purified, is also a key tenet of that. As well, being able to produce product at a low cost of goods. I think another asset of us as an organization is, as I mentioned, our key partnerships. Today you'll hear about our partnership with AbbVie, and then also in rare disease, our partnership with NS Pharma. We've developed a strong alliance management capability and the ability to manage a program with a large partner like AbbVie, we think in a way that provides robustness to our program and the potential to develop commercially in a very successful way. Today's highlight, I won't go through our entire pipeline, but certainly the highlight today and the focus of the conversation will be around our subretinal wet AMD program.
We are excited, as I mentioned, to bring top-line data this quarter, for both pivotal programs. They happen to enroll and land roughly on top of each other so we can announce the results of both programs simultaneously in what's anticipated to be a joint release with AbbVie. That will point us towards regulatory submission in 2027. As a reminder, AbbVie has ownership of the IND and will actually be doing the BLA filing process. Again, going back to the early development, I remembered the early proof of concept studies that were done in Jim Wilson's lab. The design of the program was intentional to support a design with the potential to serve a spectrum of wet AMD patients.
So an anti-VEGF fab as the gene of interest, AAV8, which is well understood as a vector in retina that has a strong safety profile, and a subretinal route of administration. These were design elements that were built into the program from the beginning and haven't really changed at all during the course of development. The biological mechanism is well understood. I think the key here was could we produce durable protein expression by going through the subretinal route? I think our recent data, five-year data, that you'll see later in more depth, shows that the necessary durability is present and a key element of the value proposition for patients. I think the other piece of this is targeted delivery.
You're in an immune privileged section of the eye at delivery, and therefore, we feel the safety database that we've built over time in this program is exceptional and comprehensive. The program moved from— There was a significant period of time at the beginning of the program on dose escalation. I believe one of the things that really strikes me on this program is the careful and methodical method at which we selected the doses that went into the pivotal study. In 2021, as we started the program, we signed the collaboration agreement with AbbVie. Very quickly, AbbVie said, "Well, U.S. only isn't going to work for us. We want this to be a global program." We began expanding the programs dramatically to not only enroll patients in the U.S. but to expand into Europe as well to support our planned global submissions.
Around that time as well, we began building our case for bilateral evidence. I think the number you will see later is roughly 50% of patients that have wet AMD also have that in fellow eye. One of the things that really differentiates, we think, our program is the potential to be able to dose the fellow eye for these patients. Some of our patients, as you will see later, have come in readily to those that are met the inclusion criteria readily come in for fellow eye treatment. The enrollment for the study completed in 2025, and we are at near or at the point of last patient last visit, and that will lead us into the top line results that we expect to show later in the quarter.
One of the things that you have seen recently as well for both our subretinal indication and also recently in diabetic retinopathy is an update on long-term durability and in particular for subretinal, again, reported five-year data, which is exceptional. So we are well positioned, we believe, to transform wet AMD care. We think we have the right treatment paradigm, a one-time administration of a gene therapy. We think there is a significant unmet need out there for patients. We will talk about that today in terms of how our development data supports the commercial thesis that we are bringing forward. We think the design of the program in terms of durability matched with safety and efficacy. All three pillars will come together nicely in the designs of our studies and what we will show versus appropriate comparators. Then the evidence that we will be able to bring to regulatory agencies.
We have had a great relationship recently with FDA in several meetings around this program, making sure that what we expect to submit with the upcoming BLA submission is what FDA is expecting. So alignment with regulatory authorities has been a primary motivation here in the last year, and we feel that we are in great shape with the agency. Then, as you will hear a little bit more about today, and a lot of the theories you will hear now about gene therapy is we know it works, but is there a market for it? Are patients interested in this new therapy? Is there a commercially feasible methodology that is available to us? We will talk in depth today about how we see that for sura-vec and how confident we are that that is an opportunity, a significant opportunity, to move this program forward.
Questions that we will try to answer today, and you are welcome later in the mission today to bring your own up. Why does wet AMD need a new treatment paradigm? Why is sura-vec uniquely positioned to address unmet need? How broad is the potential commercial opportunity for sura-vec? What is it in the clinical profile that gives us confidence? What will drive commercial adoption and global success or access? So these are elements that in the presentation we are trying to address as we now hopefully turn the page to top-line data and then the value proposition post that. We have a really strong panel of experts that we brought with us, many of which, or all of which have been part of our program over the years. Absolutely would not be standing here without this team and others beyond them that have been supporters of us.
We have Gaurav Shah, Dr. Gaurav Shah attending today, Dr. Lejla Vajzovic. Thank you for being here. Dr. Arshad Khanani, Dr. Rahul Khurana, and Dr. Ramanath Bhandari. Thank you for being here. From our agenda, you'll see that several of them will be giving presentations or in a Q&A with Ram Palanki, again, talking about the commercial prospects for the program. With that, I'll bring Leyla up to start us off.
Thank you, Karen. That was fantastic. Thank you so much. As mentioned, I'm Lejla Vajzovic. I'm a retina specialist practicing at Duke University, and it's been a true pleasure to be part of all these gene therapy programs, including sura-vec program. I am a retina surgeon, so I routinely perform surgeries, not only adults, but pediatric patients as well. I'd love to just start by all of us know that today's treatment paradigm for wet AMD has definitely changed and will hopefully change in the future as well. We know that as we had diagnosed patients in the past with wet AMD, we knew those patients will lead to central visual acuity loss. With the invent of anti-VEGF, we all were very excited to provide patients with therapy that would help them preserve that vision.
I can tell you, as I meet my brand new patient diagnosed with wet AMD, I will tell them, we very much are going to be friends. We're going to be friends for life and very frequently visit at friends for certain. I hope that I will shape with you a little bit of a paradigm that potentially having a treatment that would, yes, maintain that friendship, but really allow them to spend more time outside my office. What are we talking about when we talk about AMD in general? We know that it's a very large global health challenge that we have. 200 million patients worldwide have diagnosis of AMD, and we know it's the number one cause of severe vision loss in patients greater than 60 years of age.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProKeep exploring
